Floatz logo

Xentuzumab

Breast Neoplasms

Boehringer Ingelheimmonoclonal_antibodyPhase 2Dormant
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
65/ 100

Competitive context

177 Active assets in the Breast Neoplasms cohort.

Asset / SponsorPhaseRating
Inno-206
Merck Sharp & Dohme LLC
Phase 4BB
EXEMESTANE
Fujian Cancer Hospital
Phase 4BB
Cyclophosphamide
Merck Sharp & Dohme LLC
Phase 4BB
TAMOXIFEN
Eli Lilly and Company
Phase 3BB
Docetaxel
Universitas Airlangga
Phase 4BB

View all 50 →

Same molecule, other indications

Xentuzumab is also rated in:

neoplasmDormant
CCC
Indicative ·
52 / 100
View asset →
castration-resistant prostate carcinomaDormant
CC
Indicative ·
44 / 100
View asset →
non-small cell lung carcinomaDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →